Non-Hodgkin Lymphoma

Researchers in China have concluded that mutation of the SF3B1 gene is “significantly associated” with poorer progression-free survival and overall survival in patients with chronic lymphocytic leukemia.

Long-term results from the Nordic MCL2 and MCL3 trials showed patients with mantle cell lymphoma who are positive for minimal residual disease following allogenic stem cell transplant had significantly shorter survival.

David J. Andorsky, MD, medical oncology/hematology, Rocky Mountain Cancer Centers, discusses the phase IIIb randomized MAGNIFY study of lenalidomide (Revlimid) plus rituximab (Rituxan) followed by maintenance therapy in relapsed/refractory non-Hodgkin lymphoma, focusing on a cohort of patients with follicular lymphoma.

The FDA has granted a priority review to a new drug application for acalabrutinib for patients with previously-treated mantle cell lymphoma.

The FDA has granted acalabrutinib a breakthrough therapy designation for patients with previously-treated mantle cell lymphoma.

Kite Pharma has submitted a Marketing Authorization Application to the European Medicines Agency for axicabtagene ciloleucel (axi-cel) to treat 3 forms of non-Hodgkin lymphoma.

Treatment with CD19 chimeric antigen receptor-modified T-cell therapy induced a high response rate in patients with high-risk, ibrutinib-refractory chronic lymphocytic leukemia.

Sattva S. Neelapu, MD, discusses the latest results for axicabtagene ciloleucel (KTE-C19) for transplant-ineligible patients with relapsed/refractory non-Hodgkin lymphoma and the CAR T-cell therapy’s potential to be a new standard of care.

Loretta Nastoupil, MD, discusses the positive interim analysis and shared her thoughts on areas of future investigation for patients with relapsed follicular lymphoma.

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of obinutuzumab in the frontline setting for the treatment of patients with follicular lymphoma.

Matthew J. Matasar, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses antibody drug conjugates in B-cell malignancies.

Herve Tilly, MD, PhD, Centre Henri Becquerel, discusses a study of polatuzumab vedotin combined with rituximab (Rituxan), cyclophosphamide, doxorubicin and prednisone (PLOA-R-CHP) in patients with previously untreated diffuse large B-cell lymphoma.

Zhi Zhang Yang, MD, assistant professor of Medicine, Mayo Clinic, discusses the expression of LAG-3 defining exhaustion of intratumoral PD-1 antibodies and T cells and correlates poor outcomes in patients with follicular lymphoma.

Jia Ruan, MD, PhD, discusses some of the ongoing work in the field of T-cell lymphoma and the unanswered questions investigators are still facing for these patients